New Blood Test Better Detects Alzheimer's Disease Than Current Standard
Brain-derived pTau217 blood test shows superior accuracy for detecting Alzheimer's pathology compared to existing tests.
Summary
Researchers developed a more accurate blood test for Alzheimer's disease that specifically measures brain-derived pTau217 protein. This new test outperformed the current standard by being less affected by kidney problems and more precisely identifying brain amyloid and tau pathology. In two Chinese cohorts, the brain-specific test showed 96-98% accuracy versus 94-97% for total pTau217 testing. The improvement comes from filtering out interference from tau proteins produced outside the brain, particularly in kidneys and peripheral nerves, leading to cleaner detection of Alzheimer's-related brain changes.
Detailed Summary
Early and accurate detection of Alzheimer's disease remains crucial for timely intervention and treatment planning. Current blood tests measuring phosphorylated tau-217 (pTau217) show promise but can be confused by tau proteins from organs outside the brain.
Researchers compared a new brain-derived pTau217 (BD-pTau217) test against the standard total pTau217 test in two independent Chinese cohorts. Both groups underwent amyloid-PET brain scans to confirm actual brain pathology. The study used advanced assay technologies to measure these biomarkers with high precision.
The brain-derived test showed superior performance across multiple measures. It correlated more strongly with actual brain amyloid deposits (78-80% versus 74-77%) and achieved higher accuracy for detecting amyloid pathology (96-98% versus 94-97%). Crucially, the new test was less influenced by kidney dysfunction, showing weaker correlations with blood markers of kidney problems like urea and creatinine.
For longevity and brain health, this advancement represents a significant step toward accessible, accurate Alzheimer's screening. Earlier detection could enable preventive interventions during the preclinical phase when treatments may be most effective. The test also better identified individuals with tau pathology among those already showing amyloid deposits, enabling more precise disease staging.
However, this study focused on Chinese populations, and validation in diverse ethnic groups is needed. The technology is still emerging and not yet widely available clinically.
Key Findings
- Brain-derived pTau217 test achieved 96-98% accuracy versus 94-97% for standard pTau217 testing
- New test shows less interference from kidney dysfunction compared to current methods
- Brain-specific test better correlates with actual brain amyloid deposits seen on PET scans
- Superior identification of tau pathology enables more precise Alzheimer's disease staging
Methodology
Head-to-head comparison study using two independent Chinese cohorts with amyloid-PET brain scan confirmation. Researchers used NULISAqpcr BD-pTau217 assay versus Simoa ALZpath total p-Tau217 assay technologies for biomarker measurement.
Study Limitations
Study conducted only in Chinese populations, requiring validation across diverse ethnic groups. The brain-derived pTau217 technology is still emerging and not yet widely available for clinical use.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.